Skip to content
Prostate Cancer Research Center

Faculty of Medicine and Health Technology

Pharmacoepidemiology and Chemoprevention of Urological Cancer

2021

  1. Joentausta, RM, Rannikko, A, Murtola, TJ. Prostate Cancer-specific Survival After Radical Prostatectomy Is Improved Among Metformin Users but Not Among Other Antidiabetic Drug Users. Eur Urol Open Sci. 2021;34 :86-93. doi: 10.1016/j.euros.2021.10.002. PubMed PMID:34934970 PubMed Central PMC8655383.
  2. Eskelinen, T, Veitonmäki, T, Kotsar, A, Tammela, TLJ, Pöyhönen, A, Murtola, TJ et al.. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 2022;33 (2):313-320. doi: 10.1007/s10552-021-01527-w. PubMed PMID:34921656 PubMed Central PMC8776666.
  3. Salminen, JK, Murtola, TJ. Reply to: Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2022;150 (7):1214. doi: 10.1002/ijc.33887. PubMed PMID:34854487 .
  4. Lepomäki, M, Karhunen-Enckell, U, Tuominen, J, Kronqvist, P, Oksala, N, Murtola, T et al.. Tumor margins that lead to reoperation in breast cancer: A retrospective register study of 4,489 patients. J Surg Oncol. 2022;125 (4):577-588. doi: 10.1002/jso.26749. PubMed PMID:34779520 PubMed Central PMC9298886.
  5. Beyer, K, MacLennan, SJ, Moris, L, Lardas, M, Mastris, K, Hooker, G et al.. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. Eur Urol Focus. 2021;7 (5):943-946. doi: 10.1016/j.euf.2021.09.008. PubMed PMID:34602368 .
  6. Jasu, J, Tolonen, T, Antonarakis, ES, Beltran, H, Halabi, S, Eisenberger, MA et al.. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021;30 :47-62. doi: 10.1016/j.euros.2021.05.011. PubMed PMID:34337548 PubMed Central PMC8317817.
  7. Enwald, M, Lehtimäki, T, Mishra, PP, Mononen, N, Murtola, TJ, Raitoharju, E et al.. Human Prostate Tissue MicroRNAs and Their Predicted Target Pathways Linked to Prostate Cancer Risk Factors. Cancers (Basel). 2021;13 (14):. doi: 10.3390/cancers13143537. PubMed PMID:34298752 PubMed Central PMC8307951.
  8. Murtola, TJ, Siltari, A. Statins for Prostate Cancer: When and How Much?. Clin Cancer Res. 2021;27 (18):4947-4949. doi: 10.1158/1078-0432.CCR-21-1891. PubMed PMID:34281913 .
  9. Raittinen, PVH, Syvälä, H, Tammela, TLJ, Häkkinen, MR, Ilmonen, P, Auriola, S et al.. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine. 2021;68 :103432. doi: 10.1016/j.ebiom.2021.103432. PubMed PMID:34144486 PubMed Central PMC8219992.
  10. Santala, EEE, Artama, M, Pukkala, E, Visvanathan, K, Staff, S, Murtola, TJ et al.. Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients-A Nationwide Cohort Study. Cancers (Basel). 2021;13 (9):. doi: 10.3390/cancers13092087. PubMed PMID:33925829 PubMed Central PMC8123393.
  11. Haapiainen, H, Murtola, TJ, Raitanen, M. 3D laparoscopic prostatectomy: A prospective single-surgeon learning curve in the first 200 cases with oncologic and functional results. Scand J Urol. 2021;55 (3):242-248. doi: 10.1080/21681805.2021.1898465. PubMed PMID:33792488 .
  12. Vihervuori, VJ, Talala, K, Taari, K, Lahtela, J, Tammela, TLJ, Auvinen, A et al.. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiol Biomarkers Prev. 2021;30 (5):982-989. doi: 10.1158/1055-9965.EPI-19-0580. PubMed PMID:33653815 .
  13. Salminen, JK, Kuoppamäki, V, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2021;149 (2):307-315. doi: 10.1002/ijc.33535. PubMed PMID:33634851 .
  14. Tuokko, AT, Murtola, T, Korhonen, P, Kaipia, A. Hyperuricemia Is Not an Independent Predictor of Erectile Dysfunction. Sex Med. 2021;9 (2):100319. doi: 10.1016/j.esxm.2020.100319. PubMed PMID:33621708 PubMed Central PMC8072167.
  15. Beyer, K, Moris, L, Lardas, M, Haire, A, Barletta, F, Scuderi, S et al.. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open. 2021;11 (2):e040531. doi: 10.1136/bmjopen-2020-040531. PubMed PMID:33574142 PubMed Central PMC7880102.
  16. Siltari, A, Auvinen, A, Murtola, TJ. Pharmacoepidemiological Evaluation in Prostate Cancer-Common Pitfalls and How to Avoid Them. Cancers (Basel). 2021;13 (4):. doi: 10.3390/cancers13040696. PubMed PMID:33572236 PubMed Central PMC7914977.
  17. Siltari, A, Riikonen, J, Murtola, TJ. Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Sexual Function – A Randomized Clinical Trial. J Sex Med. 2021;18 (2):327-338. doi: 10.1016/j.jsxm.2020.11.003. PubMed PMID:33358241 .

Search PubMed

2020

  1. Siltari, A, Riikonen, J, Murtola, TJ. Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Sexual Function – A Randomized Clinical Trial. J Sex Med. 2021;18 (2):327-338. doi: 10.1016/j.jsxm.2020.11.003. PubMed PMID:33358241 .
  2. Santala, EEE, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland. Cancer Epidemiol Biomarkers Prev. 2020;29 (11):2376-2382. doi: 10.1158/1055-9965.EPI-20-0711. PubMed PMID:32917663 .
  3. Raittinen, P, Niemistö, K, Pennanen, E, Syvälä, H, Auriola, S, Riikonen, J et al.. Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer. Sci Rep. 2020;10 (1):12016. doi: 10.1038/s41598-020-68868-5. PubMed PMID:32694638 PubMed Central PMC7374714.
  4. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS One. 2020;15 (6):e0234269. doi: 10.1371/journal.pone.0234269. PubMed PMID:32598349 PubMed Central PMC7323967.
  5. Omar, MI, Roobol, MJ, Ribal, MJ, Abbott, T, Agapow, PM, Araujo, S et al.. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research. Nat Rev Urol. 2020;17 (8):482. doi: 10.1038/s41585-020-0355-3. PubMed PMID:32587405 .
  6. Omar, MI, Roobol, MJ, Ribal, MJ, Abbott, T, Agapow, PM, Araujo, S et al.. Introducing PIONEER: a project to harness big data in prostate cancer research. Nat Rev Urol. 2020;17 (6):351-362. doi: 10.1038/s41585-020-0324-x. PubMed PMID:32461687 .
  7. Riikonen, J, Pakarainen, T, Siltari, A, Pienimäki, JP, Koskimäki, J, Murtola, TJ et al.. Urine colour as an indicator for anastomotic leakage after robot-assisted radical prostatectomy. Scand J Urol. 2020;54 (3):201-207. doi: 10.1080/21681805.2020.1750474. PubMed PMID:32308088 .
  8. Kinnunen, PT, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Anticoagulants and Breast Cancer Survival: A Nationwide Cohort Study. Cancer Epidemiol Biomarkers Prev. 2020;29 (1):208-215. doi: 10.1158/1055-9965.EPI-19-0147. PubMed PMID:31653681 .
  9. Santala, EEE, Rannikko, A, Murtola, TJ. Reply to: Calcium channel blockers therapy and the risk of prostate cancer death. Int J Cancer. 2020;146 (4):1175. doi: 10.1002/ijc.32745. PubMed PMID:31633796 .

Search PubMed

2019

  1. Pylväläinen, J, Talala, K, Murtola, T, Taari, K, Raitanen, J, Tammela, TL et al.. Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time. Clin Epidemiol. 2019;11 :923-932. doi: 10.2147/CLEP.S218697. PubMed PMID:31695505 PubMed Central PMC6805117.
  2. Kinnunen, PT, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Anticoagulants and Breast Cancer Survival: A Nationwide Cohort Study. Cancer Epidemiol Biomarkers Prev. 2020;29 (1):208-215. doi: 10.1158/1055-9965.EPI-19-0147. PubMed PMID:31653681 .
  3. Santala, EEE, Rannikko, A, Murtola, TJ. Reply to: Calcium channel blockers therapy and the risk of prostate cancer death. Int J Cancer. 2020;146 (4):1175. doi: 10.1002/ijc.32745. PubMed PMID:31633796 .
  4. Siltari, A, Riikonen, J, Fode, M, Murtola, TJ. Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study. J Sex Med. 2019;16 (10):1597-1605. doi: 10.1016/j.jsxm.2019.07.001. PubMed PMID:31405764 .
  5. Santala, EEE, Kotsar, A, Veitonmäki, T, Tammela, TLJ, Murtola, TJ. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland. Scand J Urol. 2019;53 (4):185-192. doi: 10.1080/21681805.2019.1634147. PubMed PMID:31250699 .
  6. Joentausta, RM, Murtola, TJ. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591. Prostate. 2019;79 (12):1420-1421. doi: 10.1002/pros.23870. PubMed PMID:31233216 .
  7. Knuuttila, E, Riikonen, J, Syvälä, H, Auriola, S, Murtola, TJ. Access and concentrations of atorvastatin in the prostate in men with prostate cancer. Prostate. 2019;79 (12):1412-1419. doi: 10.1002/pros.23863. PubMed PMID:31231865 .
  8. Murtola, TJ, Veitonmäki, T. Aspirin and Prostate Cancer Mortality: The Role of Tumor Grading Misclassification?. Ann Intern Med. 2019;170 (7):499-500. doi: 10.7326/M19-0525. PubMed PMID:30831583 .
  9. Murtola, TJ, Syvälä, H, Riikonen, J. Reply to Jae Heon Kim and Benjamin I. Chung’s Letter to the Editor re: Teemu J. Murtola, Heimo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701. Eur Urol. 2019;75 (6):e166-e167. doi: 10.1016/j.eururo.2019.01.044. PubMed PMID:30738709 .
  10. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2019;22 (3):483-490. doi: 10.1038/s41391-019-0129-2. PubMed PMID:30696944 .
  11. Murtola, TJ, Sälli, SM, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. Prostate Cancer Prostatic Dis. 2019;22 (3):453-460. doi: 10.1038/s41391-018-0123-0. PubMed PMID:30679762 .
  12. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019;10 (1):382. doi: 10.1038/s41467-019-08293-z. PubMed PMID:30655571 PubMed Central PMC6336778.
  13. Joentausta, RM, Rannikko, A, Murtola, TJ. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79 (6):583-591. doi: 10.1002/pros.23768. PubMed PMID:30652328 .
  14. Østergren, PB, Murtola, TJ, Fode, M. Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2. Eur Urol. 2019;75 (6):938-939. doi: 10.1016/j.eururo.2018.12.016. PubMed PMID:30573315 .
  15. Häkkinen, MR, Murtola, T, Voutilainen, R, Poutanen, M, Linnanen, T, Koskivuori, J et al.. Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue. J Pharm Biomed Anal. 2019;164 :642-652. doi: 10.1016/j.jpba.2018.11.035. PubMed PMID:30472582 .
  16. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  17. Santala, EE, Rannikko, A, Murtola, TJ. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study. Int J Cancer. 2019;144 (3):440-447. doi: 10.1002/ijc.31802. PubMed PMID:30110124 .
  18. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.

Search PubMed

2018

  1. Salminen, AP, Koskinen, I, Perez, IM, Hurme, S, Murtola, TJ, Vaarala, MH et al.. Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. Eur Urol Oncol. 2018;1 (6):525-530. doi: 10.1016/j.euo.2018.06.014. PubMed PMID:31158099 .
  2. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scand J Urol. 2018;52 (5-6):321-327. doi: 10.1080/21681805.2018.1559882. PubMed PMID:30698056 .
  3. Østergren, PB, Murtola, TJ, Fode, M. Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2. Eur Urol. 2019;75 (6):938-939. doi: 10.1016/j.eururo.2018.12.016. PubMed PMID:30573315 .
  4. Häkkinen, MR, Murtola, T, Voutilainen, R, Poutanen, M, Linnanen, T, Koskivuori, J et al.. Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue. J Pharm Biomed Anal. 2019;164 :642-652. doi: 10.1016/j.jpba.2018.11.035. PubMed PMID:30472582 .
  5. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018;9 (1):4616. doi: 10.1038/s41467-018-06863-1. PubMed PMID:30397198 PubMed Central PMC6218483.
  6. Rantaniemi, L, Tammela, TLJ, Kujala, P, Murtola, TJ. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy. Scand J Urol. 2018;52 (4):269-276. doi: 10.1080/21681805.2018.1492967. PubMed PMID:30362865 .
  7. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  8. Santala, EE, Rannikko, A, Murtola, TJ. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study. Int J Cancer. 2019;144 (3):440-447. doi: 10.1002/ijc.31802. PubMed PMID:30110124 .
  9. Murtola, TJ, Syvälä, H, Tolonen, T, Helminen, M, Riikonen, J, Koskimäki, J et al.. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol. 2018;74 (6):697-701. doi: 10.1016/j.eururo.2018.06.037. PubMed PMID:30031572 .
  10. Kaapu, KJ, Rantaniemi, L, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. Sci Rep. 2018;8 (1):10308. doi: 10.1038/s41598-018-28541-4. PubMed PMID:29985440 PubMed Central PMC6037774.
  11. Dadaev, T, Saunders, EJ, Newcombe, PJ, Anokian, E, Leongamornlert, DA, Brook, MN et al.. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018;9 (1):2256. doi: 10.1038/s41467-018-04109-8. PubMed PMID:29892050 PubMed Central PMC5995836.
  12. Mäkelä, VJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors. J Urol. 2018;200 (4):743-748. doi: 10.1016/j.juro.2018.04.082. PubMed PMID:29730200 .
  13. Murtola, TJ, Vihervuori, VJ, Lahtela, J, Talala, K, Taari, K, Tammela, TL et al.. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Br J Cancer. 2018;118 (9):1248-1254. doi: 10.1038/s41416-018-0055-4. PubMed PMID:29563633 PubMed Central PMC5943324.
  14. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  15. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. Eur Urol Focus. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .

Search PubMed

2017

  1. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  2. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.
  3. Kinnunen, PTT, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. BMC Cancer. 2017;17 (1):585. doi: 10.1186/s12885-017-3579-8. PubMed PMID:28851310 PubMed Central PMC5575900.
  4. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. Eur Urol Focus. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .
  5. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  6. Eskelinen, TJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Components of metabolic syndrome and prognosis of renal cell cancer. Scand J Urol. 2017;51 (6):435-441. doi: 10.1080/21681805.2017.1352616. PubMed PMID:28743221 .
  7. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. Prostate. 2017;77 (9):1029-1035. doi: 10.1002/pros.23359. PubMed PMID:28480542 .
  8. Murtola, TJ, Virkku, A, Talala, K, Stenman, UH, Taari, K, Tammela, TLJ et al.. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use. J Urol. 2017;198 (2):305-309. doi: 10.1016/j.juro.2017.02.069. PubMed PMID:28216328 .
  9. Wettstein, MS, Saba, K, Umbehr, MH, Murtola, TJ, Fankhauser, CD, Adank, JP et al.. Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. Prostate. 2017;77 (5):549-556. doi: 10.1002/pros.23296. PubMed PMID:28093792 .
  10. Haring, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scand J Urol. 2017;51 (1):5-12. doi: 10.1080/21681805.2016.1271353. PubMed PMID:28084175 .

Search PubMed

2016

  1. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  2. Syvälä, H, Pennanen, P, Bläuer, M, Tammela, TL, Murtola, TJ. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. Biochem Biophys Res Commun. 2016;481 (1-2):46-50. doi: 10.1016/j.bbrc.2016.11.021. PubMed PMID:27833018 .
  3. Kinnunen, PT, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scand J Urol. 2016;50 (6):413-419. doi: 10.1080/21681805.2016.1228085. PubMed PMID:27628763 .
  4. Kaapu, KJ, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. Br J Cancer. 2016;115 (11):1289-1295. doi: 10.1038/bjc.2016.328. PubMed PMID:27755533 PubMed Central PMC5129833.
  5. Pennanen, P, Syvälä, H, Bläuer, M, Savinainen, K, Ylikomi, T, Tammela, TLJ et al.. The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines. Eur J Pharmacol. 2016;788 :160-167. doi: 10.1016/j.ejphar.2016.06.036. PubMed PMID:27341997 .
  6. Veitonmäki, T, Murtola, TJ, Talala, K, Taari, K, Tammela, T, Auvinen, A et al.. Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. PLoS One. 2016;11 (4):e0153413. doi: 10.1371/journal.pone.0153413. PubMed PMID:27100876 PubMed Central PMC4839624.
  7. Gusev, A, Shi, H, Kichaev, G, Pomerantz, M, Li, F, Long, HW et al.. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016;7 :10979. doi: 10.1038/ncomms10979. PubMed PMID:27052111 PubMed Central PMC4829663.
  8. Salminen, JK, Tammela, TL, Auvinen, A, Murtola, TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27 (5):637-45. doi: 10.1007/s10552-016-0737-2. PubMed PMID:27038166 .
  9. Sarre, S, Määttänen, L, Tammela, TL, Auvinen, A, Murtola, TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. Scand J Urol. 2016;50 (4):267-73. doi: 10.3109/21681805.2016.1145734. PubMed PMID:26927237 .
  10. Murtola, TJ, Karppa, EK, Taari, K, Talala, K, Tammela, TL, Auvinen, A et al.. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. Int J Cancer. 2016;138 (12):2820-8. doi: 10.1002/ijc.30017. PubMed PMID:26804670 .
  11. Murtola, TJ, Gurel, B, Umbehr, M, Lucia, MS, Thompson, IM Jr, Goodman, PJ et al.. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2016;25 (3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. PubMed PMID:26715424 PubMed Central PMC4779655.
  12. Keskiväli, T, Kujala, P, Visakorpi, T, Tammela, TL, Murtola, TJ. Statin use and risk of disease recurrence and death after radical prostatectomy. Prostate. 2016;76 (5):469-78. doi: 10.1002/pros.23138. PubMed PMID:26689439 .

Search PubMed

2015

  1. Murtola, TJ, Gurel, B, Umbehr, M, Lucia, MS, Thompson, IM Jr, Goodman, PJ et al.. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2016;25 (3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. PubMed PMID:26715424 PubMed Central PMC4779655.
  2. Keskiväli, T, Kujala, P, Visakorpi, T, Tammela, TL, Murtola, TJ. Statin use and risk of disease recurrence and death after radical prostatectomy. Prostate. 2016;76 (5):469-78. doi: 10.1002/pros.23138. PubMed PMID:26689439 .
  3. Wennberg, CL, Murtola, T, Páll, S, Abraham, MJ, Hess, B, Lindahl, E et al.. Direct-Space Corrections Enable Fast and Accurate Lorentz-Berthelot Combination Rule Lennard-Jones Lattice Summation. J Chem Theory Comput. 2015;11 (12):5737-46. doi: 10.1021/acs.jctc.5b00726. PubMed PMID:26587968 .
  4. Davies, NM, Gaunt, TR, Lewis, SJ, Holly, J, Donovan, JL, Hamdy, FC et al.. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control. 2015;26 (11):1603-16. doi: 10.1007/s10552-015-0654-9. PubMed PMID:26387087 PubMed Central PMC4596899.
  5. Szulkin, R, Whitington, T, Eklund, M, Aly, M, Eeles, RA, Easton, D et al.. Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate. 2015;75 (13):1467-74. doi: 10.1002/pros.23037. PubMed PMID:26177737 PubMed Central PMC7745998.
  6. Veitonmäki, T, Murtola, TJ, Määttänen, L, Taari, K, Stenman, UH, Tammela, TL et al.. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. Prostate. 2015;75 (13):1394-402. doi: 10.1002/pros.23020. PubMed PMID:26073992 .
  7. Amin Al Olama, A, Dadaev, T, Hazelett, DJ, Li, Q, Leongamornlert, D, Saunders, EJ et al.. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet. 2015;24 (19):5589-602. doi: 10.1093/hmg/ddv203. PubMed PMID:26025378 PubMed Central PMC4572072.
  8. Murtola, TJ, Wahlfors, T, Haring, A, Taari, K, Stenman, UH, Tammela, TL et al.. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. Eur Urol. 2015;68 (6):1089-97. doi: 10.1016/j.eururo.2015.03.026. PubMed PMID:25819720 .
  9. Stegeman, S, Amankwah, E, Klein, K, O’Mara, TA, Kim, D, Lin, HY et al.. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discov. 2015;5 (4):368-79. doi: 10.1158/2159-8290.CD-14-1057. PubMed PMID:25691096 PubMed Central PMC4390388.
  10. Kaapu, KJ, Ahti, J, Tammela, TL, Auvinen, A, Murtola, TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. Int J Cancer. 2015;137 (5):1187-95. doi: 10.1002/ijc.29470. PubMed PMID:25656312 .

Search PubMed